Biotech M&A – 2022 Deals

Biotech M&A – 2022 Deals

Biotech M&A With a Slow Start in 2022: More Deals to Follow?

DateAcquirer Co.Acquirer TickerAcquired Co.Acquired TickerDeal valuePrice/ShareNotesLink to the news PR
01/19/2022UCB, Brussels, BelgiumUCBZogenix ZGNX$1.9B$26$2 CVR, Epilepsy drughttps://prn.to/3nGq1WJ
02/14/2022Collegium PharmaceuticalCOLLBioDelivery Sciences BDSI$604M$5.6Pain Portfoliohttps://bit.ly/3rOyVnK
04/07/2022PfizerPFEReViralPrivate$525M-Antiviral targeting RSV- respiratory syncytial virushttps://bwnews.pr/3ujk7i5
04/13/2022GlaxoSmithKlineGSKSierra OncologySRRA$1.9B$55.00Momelotinib potential of myelofibrosis patients with anaemia https://bwnews.pr/3jx9wtF
04/13/2022HalozymeHALOAntares PharmaATRS$960M$5.60auto injector platformhttps://prn.to/3jA7xoo
04/19/2022RegeneronRGENCheckmate PharmaceuticalsCMPI$250M$10.50 vidutolimod, CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonisthttps://bit.ly/3Oxvhbc

For M&A 2021 full table click here https://www.chimeraresearchgroup.com/biotech-ma-2021-deals/

Recent Press

Slider

Log In

JoinLost Password?